Max Reinhardt Sells 9,321 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. (NASDAQ:PCRXGet Rating) insider Max Reinhardt sold 9,321 shares of the firm’s stock in a transaction dated Tuesday, April 19th. The shares were sold at an average price of $72.25, for a total transaction of $673,442.25. Following the completion of the sale, the insider now owns 24,238 shares in the company, valued at $1,751,195.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

PCRX stock traded up $1.29 during mid-day trading on Wednesday, reaching $75.24. The company’s stock had a trading volume of 444,742 shares, compared to its average volume of 547,079. The company has a current ratio of 1.66, a quick ratio of 1.47 and a debt-to-equity ratio of 0.92. The company’s 50 day moving average is $71.77 and its two-hundred day moving average is $62.50. Pacira BioSciences, Inc. has a fifty-two week low of $45.05 and a fifty-two week high of $82.16. The stock has a market cap of $3.37 billion, a PE ratio of 81.78 and a beta of 0.92.

Pacira BioSciences (NASDAQ:PCRXGet Rating) last posted its quarterly earnings results on Thursday, February 24th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.60 by $0.37. Pacira BioSciences had a return on equity of 14.94% and a net margin of 7.75%. The firm had revenue of $159.19 million during the quarter, compared to analysts’ expectations of $157.42 million. During the same quarter last year, the firm earned $0.63 earnings per share. The business’s revenue for the quarter was up 21.5% on a year-over-year basis. On average, analysts forecast that Pacira BioSciences, Inc. will post 3.04 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Paulson & CO. Inc. lifted its holdings in Pacira BioSciences by 35.4% in the fourth quarter. Paulson & CO. Inc. now owns 1,705,599 shares of the company’s stock valued at $102,626,000 after acquiring an additional 446,081 shares during the last quarter. Norges Bank acquired a new stake in Pacira BioSciences during the fourth quarter worth $23,557,000. Stonnington Group LLC raised its position in Pacira BioSciences by 1,386.6% in the fourth quarter. Stonnington Group LLC now owns 318,829 shares of the company’s stock valued at $19,783,000 after purchasing an additional 297,382 shares during the period. Baillie Gifford & Co. lifted its stake in shares of Pacira BioSciences by 12.8% in the 4th quarter. Baillie Gifford & Co. now owns 2,355,240 shares of the company’s stock valued at $141,714,000 after purchasing an additional 267,433 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. acquired a new position in shares of Pacira BioSciences in the 3rd quarter worth approximately $11,477,000.

Several equities research analysts have weighed in on PCRX shares. initiated coverage on Pacira BioSciences in a report on Thursday, March 31st. They issued a “hold” rating for the company. TheStreet downgraded Pacira BioSciences from a “b-” rating to a “c” rating in a research report on Thursday, February 24th. HC Wainwright raised their target price on shares of Pacira BioSciences from $86.00 to $90.00 and gave the stock a “buy” rating in a report on Friday, February 25th. JPMorgan Chase & Co. began coverage on shares of Pacira BioSciences in a report on Monday, January 3rd. They issued an “overweight” rating and a $83.00 price target on the stock. Finally, Wedbush reaffirmed a “buy” rating and set a $94.00 price target (down from $97.00) on shares of Pacira BioSciences in a research report on Saturday, February 26th. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from, the stock presently has a consensus rating of “Buy” and a consensus price target of $80.63.

Pacira BioSciences Company Profile (Get Rating)

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.

Read More

Insider Buying and Selling by Quarter for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with's FREE daily email newsletter.